Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Anu Radha Neerukonda"'
Autor:
Koosha Paydary, Aurelie Desgardin, Chih-Yi Liao, Ardaman Shergill, Natalie Marie Reizine, Stephanie Moya, Bryan Peterson, Katherine Reyes, Chanelle Robinzine, Belen Martinez-Caro Aguado, Christine Racette, Elena Ignatiev, Anu Radha Neerukonda, Yuan Ji, Blase N. Polite, Daniel V.T. Catenacci
Publikováno v:
Journal of Clinical Oncology. 40:316-316
316 Background: 5FU, Ox, Iri, and Tax are each active in upper GI cancers. Triplet cytotoxic therapies (txs) improved survival compared to doublets/singlets. However, combination of all 4 agents (FOLFOXIRITAX) has not been studied. UGT1A1 polymorphis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a205a4e957d3bd1cc52f2c29ae8567f
https://doi.org/10.1200/jco.2022.40.4_suppl.316
https://doi.org/10.1200/jco.2022.40.4_suppl.316
Autor:
Blase N. Polite, William Dale, Michael Maranzano, James A. Wallace, Selina Lai-ming Chow, Anu Radha Neerukonda
Publikováno v:
Journal of Clinical Oncology. 38:12035-12035
12035 Background: The ASCO 2018 Geriatric Oncology Guidelines support the broad application of GA to risk-stratify patients age ≥65 undergoing cancer-directed therapy. Despite this, GA has not been widely adopted due largely to perceived time and r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2ae612f5ccd41fbf617b6423615d835
https://doi.org/10.1200/jco.2020.38.15_suppl.12035
https://doi.org/10.1200/jco.2020.38.15_suppl.12035
Autor:
Anu Radha Neerukonda, Blase N. Polite, Sara Gaines, Ciro Andolfi, Terrah Paul-Olson, Lisa M. Cannon, Konstantin Umanskiy, Radhika Smith, Lai Xue, Ashley J. Williamson, Emily Steinhagen, Neil Hyman
Publikováno v:
Current problems in surgery. 55(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4d4bcc2b7961286cabc36f21b28cad7
https://pubmed.ncbi.nlm.nih.gov/29631699
https://pubmed.ncbi.nlm.nih.gov/29631699
Publikováno v:
Internal medicine (Tokyo, Japan). 55(12)
Primary autoimmune neutropenia (P-AIN) is an extremely rare disease. The most effective treatment for primary P-AIN is a granulocyte colony-stimulating factor; however, no curative treatment has been reported. We herein report a case of an adult P-AI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9fdf0cc8cfc37cfa69623dbedaee4a
https://pubmed.ncbi.nlm.nih.gov/27301525
https://pubmed.ncbi.nlm.nih.gov/27301525
Autor:
Hajime Takizawa, Anu Radha Neerukonda, Takeshi Saraya, Masachika Fujiwara, Naoki Tsujimoto, Kosuke Ohkuma
Publikováno v:
Journal of General and Family Medicine. 17:168-169
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af924d22dfe6d1b222b623dda3205f54
https://doi.org/10.14442/jgfm.17.2_168
https://doi.org/10.14442/jgfm.17.2_168
Publikováno v:
Journal of Clinical Oncology. 33:240-240
240 Background: Although elevated levels of distress have been well documented among cancer patients receiving active treatment, the magnitude of and contributors to distress in cancer survivors are yet to be well established. The purpose of this inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b20554fac27f857f1e6d7b0ff27cf1e1
https://doi.org/10.1200/jco.2015.33.29_suppl.240
https://doi.org/10.1200/jco.2015.33.29_suppl.240
Autor:
Michelle Stevens, Anu Radha Neerukonda, Lisa Reagan, Barbara Nemesure, Jules Cohen, Catherine R. Messina, Lea N. Baer
Publikováno v:
Journal of Clinical Oncology. 33:e12610-e12610
e12610 Background: Several studies have documented distress in breast cancer patients during the diagnosis and treatment phases of cancer care, however, data are more scarce regarding the prevalenc...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e456a828382d17c199067a1bf217227
https://doi.org/10.1200/jco.2015.33.15_suppl.e12610
https://doi.org/10.1200/jco.2015.33.15_suppl.e12610
Publikováno v:
Journal of Clinical Oncology. 32:e13534-e13534
e13534 Background: Inhibitors of the mammalian target of rapamycin (mTOR) pathway including everolimus and temsirolimus are currently used for the treatment of several malignancies. Their applicati...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a83521ed357a0ace02e1951f03e46c1
https://doi.org/10.1200/jco.2014.32.15_suppl.e13534
https://doi.org/10.1200/jco.2014.32.15_suppl.e13534